Approved study and prestigious meetings in fibrosis put Cereno Scientific in the limelight

20 November, 2019

Yesterday, news came that Cereno Scientific had received approval for the planned Phase II study with CS1 in Bulgaria – the second and last country to host the phase II study with CS1. BioStock contacted CEO Sten R. Sörensen, currently at an “Anti-Fibrotic Drug Development” conference in Boston, for a comment.

Read the full article on BioStock here.